Akari Therapeutics (NASDAQ:AKTX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Akari Therapeutics (NASDAQ:AKTXFree Report) in a report released on Saturday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Akari Therapeutics Price Performance

Shares of Akari Therapeutics stock opened at $1.55 on Friday. The company’s fifty day simple moving average is $1.54 and its two-hundred day simple moving average is $2.37. Akari Therapeutics has a 12-month low of $1.08 and a 12-month high of $5.50.

Institutional Trading of Akari Therapeutics

An institutional investor recently raised its position in Akari Therapeutics stock. Omnia Family Wealth LLC lifted its holdings in Akari Therapeutics, Plc (NASDAQ:AKTXFree Report) by 48.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 87,628 shares of the biopharmaceutical company’s stock after buying an additional 28,511 shares during the quarter. Omnia Family Wealth LLC owned approximately 1.55% of Akari Therapeutics worth $273,000 as of its most recent SEC filing. 5.06% of the stock is currently owned by hedge funds and other institutional investors.

Akari Therapeutics Company Profile

(Get Free Report)

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.

Featured Articles

Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.